AIP
TCRR

Ameritas Investment Partners’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Ameritas Investment Partners’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,165
Closed -$6K – 3327
2022
Q1 		$6K Hold
2,165
– – ﹤0.01% 2953
2021
Q4 		$10K Hold
2,165
– – ﹤0.01% 2916
2021
Q3 		$18K Hold
2,165
– – ﹤0.01% 2759
2021
Q2 		$36K Hold
2,165
– – ﹤0.01% 2411
2021
Q1 		$48K Hold
2,165
– – ﹤0.01% 2114
2020
Q4 		$67K Hold
2,165
– – ﹤0.01% 1816
2020
Q3 		$44K Buy
2,165
+1,191
+122% +$20.9K ﹤0.01% 1919
2020
Q2 		$15K Hold
974
– – ﹤0.01% 2522
2020
Q1 		$8K Hold
974
– – ﹤0.01% 2660
2019
Q4 		$14K Hold
974
– – ﹤0.01% 2605
2019
Q3 		$15K Buy
974
+817
+520% +$12.7K ﹤0.01% 2558
2019
Q2 		$2K Buy
+157
New +$2.5K ﹤0.01% 3030

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Ameritas Investment Partners's TCRR Position: Q2 2022 in Review

Ameritas Investment Partners sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2022, closing a stake of 2,165 shares — an estimated $6K sold.

Ameritas Investment Partners first reported a position in TCRR in Q2 2019 and held it in 12 quarters. The position peaked at $67K in Q4 2020. 83 funds tracked by Wall St. Rank hold TCRR as of Q2 2022.

  • Ameritas Investment Partners reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 2,165 TCR2 Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $6K.
  • Ameritas Investment Partners first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • Ameritas Investment Partners's TCR2 Therapeutics Inc. Common Stock position peaked at $67K in Q4 2020.
  • 83 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.